Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Immunic Inc IMUX

Healthcare Biotechnology

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively,... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IMUX)

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

PR Newswire July 27, 2023

Immunic to Participate in Scientific and Investor Conferences in July

PR Newswire June 29, 2023

Immunic to Participate in Scientific and Investor Conferences in June

PR Newswire May 30, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

PR Newswire May 17, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire May 11, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

PR Newswire May 9, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

PR Newswire May 6, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

PR Newswire May 4, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

PR Newswire April 27, 2023

Immunic to Participate in Investor and Scientific Conferences in May

PR Newswire April 26, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

PR Newswire April 5, 2023

Immunic to Participate in Investor and Scientific Conferences in March

PR Newswire March 2, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

PR Newswire February 23, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

PR Newswire February 22, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

PR Newswire February 16, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

PR Newswire February 9, 2023

Immunic to Participate in Scientific and Investor Conferences in February

PR Newswire January 25, 2023

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

PR Newswire November 17, 2022

Immunic to Participate in Investor and Scientific Conferences in November and December

PR Newswire November 10, 2022

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire November 3, 2022